Blue Trust Inc’s Fennec Pharmaceuticals FENC Stock Holding History

Blue Trust Inc’s Portfolio FENC Stock Details FENC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,367	Closed	-$21K	–	2561
2023 Q3	$21K	Buy	+2,367	New	+$19.3K	﹤0.01%	1156

Other funds holding FENC

Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return

Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return

Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

Blue Trust Inc's FENC Position: Q4 2023 in Review

Blue Trust Inc sold out of Fennec Pharmaceuticals (FENC) in Q4 2023, closing a stake of 2,367 shares — an estimated $21K sold.

Blue Trust Inc first reported a position in FENC in Q3 2023 and held it in 1 quarter. The position peaked at $21K in Q3 2023. 56 funds tracked by Wall St. Rank hold FENC as of Q4 2023.

Blue Trust Inc reported no remaining Fennec Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Blue Trust Inc sold 2,367 Fennec Pharmaceuticals shares in Q4 2023, an estimated $21K.
Blue Trust Inc first reported a position in Fennec Pharmaceuticals in Q3 2023 and held it in 1 quarter.
Blue Trust Inc's Fennec Pharmaceuticals position peaked at $21K in Q3 2023.
56 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q4 2023.

Based on Blue Trust Inc's 13F filing for Q4 2023, filed 18 Jan 2024.